Oversubscribed Series A Financing Round of Xsensio SA

Xsensio SA, a Swiss deep-tech company pioneering near real-time continuous biochemical monitoring, has closed a USD 7M oversubscribed Series A financing round. The round was led by San Francisco-based venture capital firm WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe, and Asia. The new funding will enable Xsensio to accelerate the development and clinical validation of its Lab-on-Skin© wearable biosensing platform, designed to provide dynamic, multi-modal, biochemical information to support clinical decision-making in the hospital and beyond.

Walder Wyss has advised Xsensio on this transaction. The team included Alex Nikitine (Partner, Corporate/M&A), Alice Vorburger (Managing Associate, Corporate/M&A) and Letizia Schlegel (Senior Associate, Corporate/M&A).